628.71
  Price0.77%   +4.81
(After Hours: 627.71 -1.00 -0.16%)
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
McCourt Marion EVP Commercial Aug 01 Option Exercise 342.93 1,100 377,223 20,744
McCourt Marion EVP Commercial Aug 01 Sale 581.53 1,100 639,683 19,644
McCourt Marion EVP Commercial Jul 01 Option Exercise 342.93 1,100 377,223 20,744
McCourt Marion EVP Commercial Jul 01 Sale 587.76 1,100 646,536 19,644
McCourt Marion EVP Commercial Jun 01 Option Exercise 342.93 1,100 377,223 20,744
McCourt Marion EVP Commercial Jun 01 Sale 669.51 1,100 736,461 19,644
MURPHY ANDREW J EVP Research May 17 Sale 663.68 3,543 2,351,411 58,470
MURPHY ANDREW J EVP Research May 16 Option Exercise 179.13 10,000 1,791,300 68,470
McCourt Marion EVP Commercial May 02 Option Exercise 342.93 1,100 377,223 20,744
McCourt Marion EVP Commercial May 02 Sale 656.97 1,100 722,667 19,644
RYAN ARTHUR F Director May 02 Sale 650.78 100 65,078 22,182
Landry Robert E EVP Finance CFO Apr 11 Sale 734.06 1,862 1,366,821 28,744
Fenimore Christopher R. SVP Controller Apr 08 Option Exercise 364.23 7,450 2,713,542 30,066
Landry Robert E EVP Finance CFO Apr 08 Option Exercise 386.36 8,000 3,090,840 34,744
Landry Robert E EVP Finance CFO Apr 08 Sale 737.79 325 239,780 28,744
Bassler Bonnie L Director Apr 07 Option Exercise 380.95 1,240 472,378 2,322
Landry Robert E EVP Finance CFO Apr 07 Option Exercise 399.66 1,500 599,490 30,244
Bassler Bonnie L Director Apr 07 Sale 725.00 1,240 899,000 1,082
LAROSA JOSEPH J EVP General Counsel and Secret Apr 07 Sale 721.10 5,114 3,687,705 16,900
SCHLEIFER LEONARD S President & CEO Apr 06 Sale 710.04 2,653 1,883,736 11,178
SCHLEIFER LEONARD S President & CEO Apr 05 Sale 710.05 4,461 3,167,533 13,831
McCourt Marion EVP Commercial Apr 01 Option Exercise 342.93 1,000 342,930 20,644
Landry Robert E EVP Finance CFO Apr 01 Sale 695.81 316 219,875 28,744
RYAN ARTHUR F Director Apr 01 Sale 692.81 100 69,281 22,282
McCourt Marion EVP Commercial Apr 01 Sale 701.82 1,000 701,820 19,644
LAROSA JOSEPH J EVP General Counsel and Secret Apr 01 Sale 690.73 5,114 3,532,373 22,014
Landry Robert E EVP Finance CFO Mar 31 Option Exercise 399.66 1,500 599,490 30,244
Fenimore Christopher R. SVP Controller Mar 31 Option Exercise 317.97 12,000 3,815,640 31,628
SCHLEIFER LEONARD S President & CEO Mar 31 Sale 710.01 2,886 2,049,089 18,292
BROWN MICHAEL S Director Mar 30 Option Exercise 374.12 408 152,641 1,490
GOLDSTEIN JOSEPH L Director Mar 30 Option Exercise 374.12 2,431 909,486 8,513
Bassler Bonnie L Director Mar 30 Option Exercise 380.95 1,240 472,378 2,322
Bassler Bonnie L Director Mar 30 Sale 700.00 1,240 868,000 1,082
VAGELOS P ROY Director Mar 30 Sale 700.01 28,572 20,000,686 23,461
GOLDSTEIN JOSEPH L Director Mar 30 Sale 700.00 2,431 1,701,700 6,082
BROWN MICHAEL S Director Mar 30 Sale 699.00 408 285,192 1,082
BROWN MICHAEL S Director Mar 29 Option Exercise 374.12 1,522 569,411 2,604
BROWN MICHAEL S Director Mar 29 Sale 699.00 1,522 1,063,878 1,082
Landry Robert E EVP Finance CFO Mar 29 Sale 687.90 2,683 1,845,630 28,744
Landry Robert E EVP Finance CFO Mar 28 Option Exercise 426.56 14,500 6,185,095 34,293
Tessier-Lavigne Marc Director Mar 21 Option Exercise 380.95 7,439 2,833,887 9,708
Landry Robert E EVP Finance CFO Mar 21 Option Exercise 381.92 400 152,768 29,056
Landry Robert E EVP Finance CFO Mar 21 Sale 693.00 300 207,900 28,656
Tessier-Lavigne Marc Director Mar 21 Sale 690.00 7,439 5,132,910 2,269
Tessier-Lavigne Marc Director Mar 17 Option Exercise 376.69 7,830 2,949,483 10,099
Landry Robert E EVP Finance CFO Mar 17 Option Exercise 381.92 365 139,401 29,242
Tessier-Lavigne Marc Director Mar 17 Sale 680.00 7,830 5,324,400 2,269
Landry Robert E EVP Finance CFO Mar 17 Sale 686.00 83 56,938 28,877
Tessier-Lavigne Marc Director Mar 16 Option Exercise 374.12 4,361 1,631,537 6,630
Zoghbi Huda Y Director Mar 16 Option Exercise 391.92 2,000 783,840 3,082
Tessier-Lavigne Marc Director Mar 16 Sale 675.00 4,361 2,943,675 2,269
Landry Robert E EVP Finance CFO Mar 16 Sale 677.00 300 203,100 28,960
Zoghbi Huda Y Director Mar 16 Sale 675.00 2,000 1,350,000 1,082
VAGELOS P ROY Director Mar 14 Option Exercise 179.13 75,000 13,434,750 393,669
McCourt Marion EVP Commercial Mar 01 Option Exercise 342.93 1,000 342,930 20,644
McCourt Marion EVP Commercial Mar 01 Sale 615.39 1,000 615,390 19,644
RYAN ARTHUR F Director Mar 01 Sale 618.37 100 61,837 22,382
SING GEORGE L Director Feb 28 Sale 615.50 2,000 1,231,000 26,049
SING GEORGE L Director Feb 25 Sale 621.00 2,000 1,242,000 28,049
BROWN MICHAEL S Director Feb 23 Sale 608.68 500 304,340 7,162
Van Plew Daniel P EVP & General Mgr, Industrial Feb 23 Sale 613.99 6,781 4,163,489 30,578
Van Plew Daniel P EVP & General Mgr, Industrial Feb 22 Option Exercise 399.66 40,000 15,986,400 70,578
MURPHY ANDREW J EVP Research Feb 15 Sale 629.34 3,540 2,227,851 58,470
MURPHY ANDREW J EVP Research Feb 14 Option Exercise 179.13 10,000 1,791,300 68,470
McCourt Marion EVP Commercial Feb 01 Option Exercise 342.93 1,000 342,930 20,644
RYAN ARTHUR F Director Feb 01 Sale 607.14 100 60,714 22,482
McCourt Marion EVP Commercial Feb 01 Sale 607.46 1,000 607,460 19,644
McCourt Marion EVP Commercial Jan 03 Option Exercise 342.93 1,000 342,930 20,644
RYAN ARTHUR F Director Jan 03 Sale 624.95 100 62,495 22,391
McCourt Marion EVP Commercial Jan 03 Sale 625.00 1,000 625,000 19,644
YANCOPOULOS GEORGE President and Chief Scientific Dec 22 Option Exercise 221.08 442,267 97,775,813 1,169,835
McCourt Marion EVP Commercial Dec 13 Sale 653.12 344 224,673 19,644
Landry Robert E EVP Finance CFO Dec 13 Sale 662.50 116 76,850 29,260
Landry Robert E EVP Finance CFO Dec 10 Option Exercise 555.67 1,500 833,505 31,457
MURPHY ANDREW J EVP Research Dec 10 Sale 666.27 7,122 4,745,202 59,167
Landry Robert E EVP Finance CFO Dec 10 Sale 666.42 781 520,477 29,957
Tessier-Lavigne Marc Director Dec 09 Option Exercise 371.40 3,784 1,405,378 5,862
Landry Robert E EVP Finance CFO Dec 09 Option Exercise 399.66 4,250 1,698,555 34,207
LAROSA JOSEPH J EVP General Counsel and Secret Dec 09 Option Exercise 179.13 30,000 5,373,900 46,520
MURPHY ANDREW J EVP Research Dec 09 Option Exercise 52.03 16,500 858,495 75,667
Tessier-Lavigne Marc Director Dec 09 Sale 665.00 3,784 2,516,360 2,078
STAHL NEIL EVP Research and Development Dec 03 Option Exercise 179.13 72,500 12,986,925 101,309
McCourt Marion EVP Commercial Dec 01 Option Exercise 342.93 1,000 342,930 18,038
McCourt Marion EVP Commercial Dec 01 Sale 639.13 1,000 639,130 17,038
RYAN ARTHUR F Director Dec 01 Sale 637.53 100 63,753 22,491
SING GEORGE L Director Nov 22 Sale 657.50 2,000 1,315,000 29,858
SCHLEIFER LEONARD S President & CEO Nov 19 Option Exercise 221.08 520,313 115,030,120 651,568
SING GEORGE L Director Nov 19 Sale 655.00 1,000 655,000 31,858
SING GEORGE L Director Nov 18 Sale 650.00 4,000 2,600,000 32,858
Landry Robert E EVP Finance CFO Nov 17 Sale 645.08 681 439,299 25,986
Landry Robert E EVP Finance CFO Nov 16 Option Exercise 399.66 3,750 1,498,725 29,736
SING GEORGE L Director Nov 16 Sale 650.00 750 487,500 1,000
SING GEORGE L Director Nov 16 Sale 656.26 6,000 3,937,580 36,858
MURPHY ANDREW J EVP Research Nov 16 Sale 647.17 7,167 4,638,263 55,705
Van Plew Daniel P EVP & General Mgr, Industrial Nov 16 Sale 656.86 6,778 4,452,194 26,931
Van Plew Daniel P EVP & General Mgr, Industrial Nov 15 Option Exercise 270.43 25,000 6,760,750 51,931
MURPHY ANDREW J EVP Research Nov 15 Option Exercise 52.03 16,579 862,605 72,284
McCourt Marion EVP Commercial Nov 01 Option Exercise 342.93 1,000 342,930 18,038
RYAN ARTHUR F Director Nov 01 Sale 642.52 100 64,252 23,091
McCourt Marion EVP Commercial Nov 01 Sale 640.00 1,000 640,000 17,038
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Cap:    |  Volume (24h):